CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation
- 14 July 2020
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 452-459
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (DK065988)
- University of North Carolina at Chapel Hill
- Hospital for Sick Children
- Cystic Fibrosis Foundation (HAGGIE19R2)
- Cystic Fibrosis Foundation (HAGGIE20XX0)
- Cystic Fibrosis Foundation (BOUCHE15R0)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK072517)
This publication has 28 references indexed in Scilit:
- Cystic fibrosisThe Lancet, 2016
- Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: Importance of functional studies to establish disease liability of mutationsJournal of Cystic Fibrosis, 2016
- The road for survival improvement of cystic fibrosis patients in Arab countriesInternational Journal of Pediatrics and Adolescent Medicine, 2015
- Cystic fibrosis genetics: from molecular understanding to clinical applicationNature Reviews Genetics, 2014
- Genetic, cell biological, and clinical interrogation of theCFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical interventionGenetics in Medicine, 2014
- Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator geneNature Genetics, 2013
- Influence of cell background on pharmacological rescue of mutant CFTRAmerican Journal of Physiology-Cell Physiology, 2010
- High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput ScreeningJournal of Biological Chemistry, 2002
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitiveNature, 1992